📰 Aematologic News
Aematologic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Aematologic. Real-time updates on events, politics, business and more.
December 13, 2023
Sickle cell disease, a group of inherited blood disorders, affects around 100,000 individuals in the United States and is predominant among African Americans.
June 2, 2023
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of... | June 2, 2023
June 1, 2023
Syros Pharmaceuticals , a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock... | June 1, 2023
May 22, 2023
By Denny Jacob Blueprint Medicines on Monday said the Food and Drug Administration approved ayvakit as a treatment for adults with indolent systemic mastocytosis, a hematologic disorder that... | May 22, 2023
May 11, 2023
AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger
May 5, 2023
SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,... | May 5, 2023
April 20, 2023
SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,... | April 20, 2023
April 17, 2023
GRAIL's Methylation Assay Had 92% Cancer Detection Rate Across Six Hematologic Malignancies With 96% Accuracy in Determining the Hematologic Malignancy Subtype Findings Support Use of GRAIL's Methylation
April 12, 2023
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignanciesSEATTLE, April 12, 2023 -- Adaptive... | April 12, 2023
March 31, 2023
IMV Inc. , a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March... | March 31, 2023